Company: INDP
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010099
Chunk: 47

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 1
Chunk 47
---
, pursuant to which we sold and issued to certain investors, 1,643,837 shares of
common stock. In addition, in a concurrent private placement, we issued to the investors unregistered warrants to purchase 1,643,837
shares of common stock. The combined purchase price for one share of common stock and one warrant was $1.825, resulting in gross proceeds
of approximately $3.0 million.

4

In
June 2022, we entered into an At The Market Offering Agreement (the “ATM Agreement”) which was amended on September 1, 2022
with H.C. Wainwright & Co., LLC, as sales agent (“Wainwright”), pursuant to which we may offer and sell, from time to
time through Wainwright, shares of our common stock, par value $0.01 per share, for aggregate gross proceeds of up to $3.7 million. The
issuance and sale of common stock by us under the ATM Agreement is being made pursuant to our effective “shelf” registration
statement on Form S-3 filed with the SEC on September 1, 2022 and declared effective on September 9, 2022. In 2024, we sold 152,000 shares
of our common stock for aggregate gross proceeds of approximately $0.4 million. On August 6, 2024, we filed a prospectus supplement to
reduce the amount of shares registered under the prospectus for the ATM to $0.00 and to suspend the ATM program, but the ATM Agreement
remains in full force and effect.

As of the date of the issuance of this Quarterly Report and based on our
current operating plan, we will need to obtain additional capital to fund our ongoing activities beyond the second quarter of 2025. We will need to increase our
capital resources through equity or debt financings, and we may need to do so sooner than we expect. We may also seek to finance our
cash needs through collaborations, strategic alliances, or license agreements with third parties. If sources of financing are available,
they may result in substantial dilution to our stockholders. We cannot provide any assurance that new financing will be available to
us on commercially acceptable terms or in the amounts required, if at all. If we are unable to consummate a financing or other transaction,
we may need to delay, reduce, or eliminate our research and development programs, which could adversely affect our business prospects,
or cease operations